Protocol Ledger

NCT07204275 · Phase II/III · RECRUITING

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Interventional Phase II/III clinical trial protocol NCT07204275 sponsored by Vertex Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-30 Enrollment: 176 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07204275
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)176 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07204275
Protocol FieldVerified Registry Value
NCT IdentifierNCT07204275
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment176 participants (ESTIMATED)
Registered Start Date2025-09-30
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI